Everything The companies Informed You Regarding BMS-754807 Is actually Dead Wrong

5 mmol/L [ IU/d [95% CI, �C17.2 to �C5.2] for empagliflozin 25 mg, PPFKM of patients (Table 4), while genital infections were more common in both empagliflozin groups than in the placebo group (Table 4). Besides insulin, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are also commonly used injected glucose-lowering agents in T2DM. A combination of an SGLT2 inhibitor and a GLP-1 RA would be ideal in many respects, particularly regarding the potential combined weight loss. To date, no clinical trial results of SGLT2 inhibitors in combination with a GLP-1 RA have been published, although one such trial is known to be underway, assessing the combination of canagliflozin and IGF-1R inhibitor liraglutide (ClinicalTrials.gov identifier: BLZ945 in vivo NCT02324842). Preliminary reports indicate that clinicians are trying the SGLT2 inhibitor/GLP-1 RA combination in clinical practice, and suggest additional weight loss is typically observed, although the study sizes have been fairly small.36,37 Achieving target HbA1c ADA guidelines, lowering HbA1c to